Overall Survival Benefit and Long-Term Safety of Romiplostim in Persistent Chemotherapy-Induced Thrombocytopenia - Quiz - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Long-Term Efficacy and Safety Profile of Romiplostim in Patients with Persistent Thrombocytopenia Following Chemotherapy

  • By

  • Andrew B. Song

  • Gerald A. Soff

  • September 28, 2026

Share

Original Source(s)

Overall Survival Benefit and Long-Term Safety of Romiplostim in Persistent Chemotherapy-Induced Thrombocytopenia

  • by Andrew B. Song, Gerald A. Soff

  • September 28, 2026

Related Content

Daratumumab ± pomalidomide maintenance after salvage autologous transplantation in relapsed multiple myeloma: a phase 2 study

Deep learning-based segmentation of peritoneal cancer index regions from CT imaging

Multicentre evaluation of artificial intelligence risk classification for detection of clinically significant prostate cancer on biparametric MRI